AUCTORES
Globalize your Research
Research Article | DOI: https://doi.org/ 10.31579/2768-0487/008
1Advisor in Pediatrics and Pediatric Psychiatry, Children Teaching Hospital of Baghdad Medical City, Head, Iraq Headquarter of Copernicus Scientists International Panel, Baghdad, Iraq.
*Corresponding Author: Aamir Jalal Al Mosawi, 1Advisor in Pediatrics and Pediatric Psychiatry, Children Teaching Hospital of Baghdad Medical City, Head, Iraq Headquarter of Copernicus Scientists International Panel, Baghdad, Iraq.
Citation: Aamir Jalal Al Mosawi. (2021) Trump’s covid-19 treatment: Can we offer it to other patients in the world. Journal of Clinical and Laboratory Research. 2(2) DOI: 10.31579/2768-0487/008
Copyright: ©2021 Aamir Jalal Al Mosawi. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 08 February 2021 | Accepted: 19 February 2021 | Published: 25 February 2021
Keywords: Trump’s covid-19; evidence-based therapies; medical ethics
Background: Covid-19 is a viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first reported during December, 2019, in Wuhan, Hubei in China. On Thursday, the first of October 2020, the White House of the USA declared that the president of the USA, Donald Trump had a positive test for SARS-CoV-2. He initially had mild symptoms which included mostly, hoarseness, lethargy, and fatigue. The treatment received by a patient “Donald Trump” who was considered the most powerful person in the world is studied, and this paper assumed that all the patients in the world are as important as Mr. Trump and tries to offer the best evidence-treatment for them.
Patients and methods: Most media including the CNN television channel rightly confirmed that Mr. Trump has been treated by the best doctors in the world with best therapies that could possibly help him in defeating the virus. The CNN, in various programs during the first week of October, emphasized that, American citizens with Covid-19 are not receiving the same treatments as their president Donald Trump. Results: Trump aged 74 years and initially had mild symptoms which included mostly, hoarseness, lethargy, and fatigue. His age, obesity and mildly elevated cholesterol were considered risk factors that may reduce the likelihood of having very favorable outcome. It was reported that he initially took hydroxychloroquine, an anti-malarial drug. The use of a therapeutic approach including experimental antibody therapy, remdesivir and dexamethasone has not been reported as a treatment for one patient before other than Mr. Trump. Obviously, of the three important therapies, only dexamethasone can be offered to almost all the patients with covid-19.
Conclusion: It seems that, the most important factors that made treatment of Donald Trump effective and successful are:
1-The early institution of therapy regardless of the generally accepted recommendations.
2-The use of multiple drugs as none of the available drug alone can guarantee successful treatment.
Covid-19 is a viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first reported during December, 2019, in Wuhan, Hubei in China [1, 2, 3].
There are four genera of coronaviruses including alpha-coronaviruses, beta-coronaviruses, gamma-coronaviruses, and delta -coronaviruses. Alpha and beta-coronavirus can infect mammals, while gamma-coronavirus and delta-coronavirus generally infect birds.
Four coronaviruses are known to cause mild upper respiratory infection in humans of all ages including infants. The transmission of coronaviruses from animals (birds) to causes respiratory illness has been reported as early as 1969 by Kapikian et al. Community-wide outbreak associated with 229E-like coronavirus has be reported as early as 1970 by Cavallaro and Monto. Until December, 2020, two beta-coronaviruses (SARS coronaviruses and MERS-coronaviruses were known to cause severe, potentially fatal pneumonia-like illness [1-6].
Errors in the replication of viral genomic RNA of zoonotic coronaviruses led to the emergence of genetically related diverse quasi-species, while the transmission of some of them to a new host species led to the emergence of human severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). SARS-CoV emerged for the first time in Guangdong China in 2002 spread rapidly to many other counties causing more than 8000 cases with about10% mortality. In 2012, it was thought that MERS-CoV was transmitted to humans from bats through an intermediate camel host leading to 1700 cases in 27 countries with about 40% mortality [1-6].
The disease has rapidly became a worldwide pandemic, and according to the live online update available at https:// www.worldometers.info/coron avirus/ , on the 6th of October, 2020, The disease affected more than 35.5 million person throughout the world, and was associated with more than 1.04 million deaths. In a country like Iraq, many doctors died from covid-19 and persons whom were considered to be healthy and possibly having a good immunity like former football players and a bodybuilding champion [7]
The incubation period of the disease is from one day to fourteen days. The disease is commonly associated with fever, cough, fatigue, shortness of breath or breathing difficulties, and loss of smell and taste [7].
Although, most patients have mild symptoms, some patients experience acute respiratory distress syndrome possibly that is generally attributed to cytokine storm. Severe disease can be complicated by septic shock, vascular thrombosis and multi-organ failure [1, 2, 3].
Patients can infect others two days before the symptom onset and the disease can be transmitted from asymptomatic persons. Patients may remain infectious for seven to twelve days in moderate cases and up to two weeks in severe cases. The standard method for diagnosing the disease is real-time reverse transcription polymerase chain reaction (rRT-PCR) from a nasopharyngeal swab [4, 5, 6].
SARS-CoV-2 has already defeated the efforts to prevent its spread and caused probably the most global pandemic in history. SARS-CoV-2 continued to infect people and to take lives without the emergence of a treatment that is confirmed to have clinically a significant effectiveness in clinical treatment. The rational scientific approach to face a potentially fatal viral pandemic with no known effective specific therapies dictate the early use of all the useful preliminary research evidence with prioritizing emphasis on safety to avoid making more harm than good in such situation[4,5,6].
The treatment received by a patient “Donald Trump” who was considered the most powerful person in the world is studied, and this paper assumed that all the patients in the world are as important as Mr. Trump and tries to offer the best evidence-treatment for them.
On Thursday, the first of October 2020, the White House of the USA declared that the president of the USA Donald Trump, his wife, and other White House officials had a positive test for SARS-CoV-2.
He aged 74 years and initially had mild symptoms which included mostly, hoarseness, lethargy, and fatigue. His age, obesity and mildly elevated cholesterol were considered risk factors that may reduce the likelihood of having very favorable outcome. It was reported that he initially took hydroxychloroquine, an anti-malarial drug.
In fact, during May, 2020 Mr. Trump reported that he has taken a two-week-long preventive dose of hydroxychloroquine. On Friday, Trump developed fever, marked fatigue, difficulty in breathing with some lowering of oxygen saturation, a treatment with Regeneron’s experimental cocktail of two monoclonal antibodies, and remdesivir (a five-day course) was started. He received 8 g intravenous infusion of Regeneron’s mixture, which is the highest dose used in the treatment of 245 individual in an unpublished clinical trial conducted by Regeneron. Regeneron’s antibodies were used to treat non-hospitalized patients to augment the immune response, and possibly reduce viral load.
Trump was Hospitalized for three days at Walter Reed National Military Medical Center, and left the hospital on Monday night. On Saturday, Trump needed supplemental because of the lowered oxygen saturation and he was given two doses of dexamethasone. On the second of October, Trump’s doctors also reported that he was also receiving daily aspirin, melatonin, zinc, and famotidine.
Most media including the CNN television channel rightly confirmed that Mr. Trump has been treated by the best doctors in the world with best therapies that could possibly help him in defeating the virus. Dr Sean Conley (Figure-1) was probably the most important doctor who was in charge of the treatment of Mr. Trump.
In addition, the CNN, in various programs during the first week of October, emphasized that, American citizens with Covid-19 are not receiving the same treatments as their president Donald Trump.
The use of a therapeutic approach including experimental antibody therapy, remdesivir and dexamethasone has not been reported as a treatment for one patient before other than Trump.
Assuming that Mr. Trump is an ordinary man in this world, we will find, and that of the three medications that are considered most important, only dexamethasone can be offered to almost all the patients with covid-19 throughout the world.
However, other medications, he received such as famotidine and melatonin are also generally available for most people in the world or can be easily available for most people.
Before Trump was tested positive, and considering him at a high risk, he received oral hydroxychloroquine as a preventive measure. Trump was possibly also receiving hydroxychloroquine very early during the time when tested positive for SARS-CoV-2.
However, because of the potential occurrence of side effect that demands regular medical supervision, we recommend the use of oral azithromycin 500 mg tablets daily as a preventive measure.
For positive asymptomatic patients, we recommend the use of oral azithromycin 500 mg twice daily or oral azithromycin 500 mg tablets daily plus low dose oral hydroxychloroquine 200 mg once daily. For patients with positive test who have mild symptoms, it will be useful to add melatonin 5 mg at night which will probably help with symptomatic control of cough and possibly help in the prevention of the cytokine storm.
When Trump developed the symptom of fever and difficulty of breathing treatment with remdesivir and Regeneron’s antibody mixture was rapidly instituted before hospitalization. These two medications are generally not available for most patients throughout the world at this stage of illness.
Therefore, if Trump was an ordinary man in this world we recommend the following therapies at this stage:
1-Intravenous or intramuscular Teicoplanin in the doses suggested by Sato et al (2006) [4, 5, 6]. A loading dose of 400 or 800 mg can be given on the first day, followed by maintenance dose of 400mg.
2-Oral azithromycin 500 mg twice daily.
3-Oral Famotidine.
4-Oral melatonin 5 mg daily at night.
5-Low dose of hydroxychloroquine 200mg can also be considered in patients with health hearts.
6-Dexamethasone can be given based on the clinical judgment.
Dr. Sean Conley said “Trump has also received dexamethasone, a cheap and widely available corticosteroid that can reduce inflammation. But it also suppresses the immune system, so it's generally not recommended for Covid-19 patients unless the situation is severe”.
Trump’s was given Regeneron antibody mixture despite there was no published study describing its use. However, Regeneron press reported that experiments using golden hamsters and rhesus macaques that were intentionally infected with SARS-CoV-2 were associated with reduction of the viral levels and disease pathology. Regeneron reported that in an ongoing unpublished clinical trial in individuals (asymptomatic or have moderate) who tested positive for SARS-CoV-2, Antibody treatment reduced viral load and shortened symptomatic disease in patients who did not have SARS-CoV-2 antibodies at the initiation of the study. It was not possible to enroll Trump in the ongoing unpublished clinical trial because, it randomly assigns half the participants to receive the antibodies; while the other half of the patients are enrolled in the control group and receive infusions of an inactive placebo [7].
The United States Food and Drug Administration (FDA) regulation allows minor expanded access experimental treatments and treating physicians need to request what is called “A compassionate use” of an investigational new drug for individual patients or for emergencies [7].
Remdesivir is a drug that can be given intravenously and not orally. It has an anti-viral against several RNA viruses. It has an in vitro antiviral activity against filoviruses, arenaviruses, and coronaviruses including circulating human coronaviruses HCoV-OC43, HCoV-229E, SARS, and MERS zoonotic coronaviruses. Remdesivir (GS-5734) is a monophosphoramidate prodrug of an adenosine analogue that is activated intra-cellularly to the main metabolite in plasma “GS-441524” which acts mainly by interfering with the action of viral RNA-dependent RNA polymerase and escapes proofreading by viral exoribonuclease resulting reducing in viral RNA replication [1-8].
Warren et al (2016) reported that remdesivir has an antiviral activity against multiple variants of Ebola virus and other filoviruses in cell-based assays. Nonhuman primates receiving intravenous remdesivir had persistent nucleoside triphosphate levels in peripheral blood mononuclear cells (half-life:14 hours) and distribution to sites of viral replication in the testes, eyes, and brain. In a rhesus monkey model of Ebola virus disease, once-daily remdesivir intravenous administration of 10 mg/kg for 12 days was associated with a great suppression of Ebola virus replication and therefore protected 100% of Ebola virus-infected animals against fatal disease. Treatment also improved the clinical and pathophysiological markers, even when treatments were started three days after virus exposure when systemic viral RNA was detected in two out of six treated animals. Warren et al suggested that remdesivir important post-exposure protection against Ebola virus disease in nonhuman primates [9].
Sheahan et al (2017) showed that remdesivir can inhibit SARS-CoV and MERS-CoV replication in multiple in vitro systems, including primary human airway epithelial cell cultures with submicromolar IC50 values. Remdesivir can also inhibit bat CoVs, pre-pandemic bat CoVs, and circulating contemporary human CoV in primary human lung cells. In a mouse model of SARS-CoV pathogenesis, prophylactic and early therapeutic administration of remdesivir considerably decreased lung viral load and was associated with clinical improvement and also improved respiratory function [8].
Agostini et al (2018) reported that remdesivir can effectively inhibit human and zoonotic coronaviruses in vitro and in a severe acute respiratory syndrome coronavirus (SARS-CoV) mouse model. They also showed that remdesivir can inhibit murine hepatitis virus (MHV) with similar 50
It seems that, the most important factors that made treatment of Donald Trump effective and successful are:
1-The early institution of therapy regardless of the generally accepted recommendations.
2-The use of multiple drugs as none of the available drug alone can guarantee successful treatment.
Assuming that all patients in the world are as important as Mr. Trump and offering them the best evidenced-based therapies as early as possible.
We recommend the use of oral azithromycin 500 mg tablets daily as a preventive measure for high risk individuals.
We recommend the use of oral azithromycin 500 mg twice daily or oral azithromycin 500 mg tablets daily plus low dose oral hydroxychloroquine 200 mg once daily for asymptomatic patients who tested positive.
For patients with positive test who have mild symptoms, it will be useful to add melatonin 5 mg at night which will probably help with symptomatic control of cough and possibly help in the prevention of the cytokine storm.
For patients with difficulty in breathing who don’t have the access to treatment with remdesivir and Regeneron’s antibody mixture, we recommend early use of the following therapies at this stage:
1-Intravenous or intramuscular Teicoplanin in the doses suggested by Sato et al (2006) [4, 5, 6, 7]. A loading dose of 400 or 800 mg can be given on the first day, followed by maintenance dose of 400mg.
2-Oral azithromycin 500 mg twice daily.
The sketch in figure-1 was published before in our previous publication and the author has their copyright.
Non
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
